192 related articles for article (PubMed ID: 11556845)
1. The topology of plasminogen binding and activation on the surface of human breast cancer cells.
Andronicos NM; Ranson M
Br J Cancer; 2001 Sep; 85(6):909-16. PubMed ID: 11556845
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
Stillfried GE; Saunders DN; Ranson M
Breast Cancer Res; 2007; 9(1):R14. PubMed ID: 17257442
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression.
Sharma MR; Koltowski L; Ownbey RT; Tuszynski GP; Sharma MC
Exp Mol Pathol; 2006 Oct; 81(2):146-56. PubMed ID: 16643892
[TBL] [Abstract][Full Text] [Related]
4. Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis.
He Y; Liu XD; Chen ZY; Zhu J; Xiong Y; Li K; Dong JH; Li X
Clin Cancer Res; 2007 Jun; 13(11):3115-24. PubMed ID: 17545513
[TBL] [Abstract][Full Text] [Related]
5. Increased plasminogen binding is associated with metastatic breast cancer cells: differential expression of plasminogen binding proteins.
Ranson M; Andronicos NM; O'Mullane MJ; Baker MS
Br J Cancer; 1998 May; 77(10):1586-97. PubMed ID: 9635833
[TBL] [Abstract][Full Text] [Related]
6. Binding and activation of plasminogen on the surface of osteosarcoma cells.
Campbell PG; Wines K; Yanosick TB; Novak JF
J Cell Physiol; 1994 Apr; 159(1):1-10. PubMed ID: 7511144
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activator inhibitor type 2 inhibits cell surface associated tissue plasminogen activator in vitro: potential receptor interactions.
Lobov S; Croucher DR; Saunders DN; Ranson M
Thromb Haemost; 2008 Aug; 100(2):319-29. PubMed ID: 18690354
[TBL] [Abstract][Full Text] [Related]
8. Endothelial cells and normal breast epithelial cells enhance invasion of breast carcinoma cells by CXCR-4-dependent up-regulation of urokinase-type plasminogen activator receptor (uPAR, CD87) expression.
Serratì S; Margheri F; Fibbi G; Di Cara G; Minafra L; Pucci-Minafra I; Liotta F; Annunziato F; Pucci M; Del Rosso M
J Pathol; 2008 Apr; 214(5):545-54. PubMed ID: 18189329
[TBL] [Abstract][Full Text] [Related]
9. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
10. Loss of cell viability dramatically elevates cell surface plasminogen binding and activation.
O'Mullane MJ; Baker MS
Exp Cell Res; 1998 Jul; 242(1):153-64. PubMed ID: 9665813
[TBL] [Abstract][Full Text] [Related]
11. Binding and activation of plasminogen at the surface of human keratinocytes.
Reinartz J; Batrla R; Boukamp P; Fusenig N; Kramer MD
Exp Cell Res; 1993 Sep; 208(1):197-208. PubMed ID: 8359216
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer cell surface annexin II induces cell migration and neoangiogenesis via tPA dependent plasmin generation.
Sharma M; Ownbey RT; Sharma MC
Exp Mol Pathol; 2010 Apr; 88(2):278-86. PubMed ID: 20079732
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the invasion-metastasis mechanism in pancreatic cancer: involvement of plasmin(ogen) cascade proteins in the invasion of pancreatic cancer cells.
Tan X; Egami H; Nozawa F; Abe M; Baba H
Int J Oncol; 2006 Feb; 28(2):369-74. PubMed ID: 16391791
[TBL] [Abstract][Full Text] [Related]
14. Receptor mediated binding of the fibrinolytic components, plasminogen and urokinase, to peripheral blood cells.
Miles LA; Plow EF
Thromb Haemost; 1987 Oct; 58(3):936-42. PubMed ID: 2829380
[TBL] [Abstract][Full Text] [Related]
15. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
16. Stimulation of human breast carcinoma cell invasiveness and urokinase plasminogen activator activity by glucose deprivation.
Belkacemi L; Lam E; Caldwell JD; Siemens DR; Graham CH
Exp Cell Res; 2006 Jun; 312(10):1685-92. PubMed ID: 16564525
[TBL] [Abstract][Full Text] [Related]
17. Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors.
Tan M; Li P; Sun M; Yin G; Yu D
Oncogene; 2006 Jun; 25(23):3286-95. PubMed ID: 16407820
[TBL] [Abstract][Full Text] [Related]
18. Urokinase-type plasminogen activator system and breast cancer (Review).
Han B; Nakamura M; Mori I; Nakamura Y; Kakudo K
Oncol Rep; 2005 Jul; 14(1):105-12. PubMed ID: 15944776
[TBL] [Abstract][Full Text] [Related]
19. Differential binding of plasminogen, plasmin, and angiostatin4.5 to cell surface beta-actin: implications for cancer-mediated angiogenesis.
Wang H; Doll JA; Jiang K; Cundiff DL; Czarnecki JS; Wilson M; Ridge KM; Soff GA
Cancer Res; 2006 Jul; 66(14):7211-5. PubMed ID: 16849568
[TBL] [Abstract][Full Text] [Related]
20. Discriminating between cell surface and intracellular plasminogen-binding proteins: heterogeneity in profibrinolytic plasminogen-binding proteins on monocytoid cells.
Hawley SB; Green MA; Miles LA
Thromb Haemost; 2000 Nov; 84(5):882-90. PubMed ID: 11127872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
